vs
Embecta Corp.（EMBC）与FirstCash Holdings, Inc.（FCFS）财务数据对比。点击上方公司名可切换其他公司
FirstCash Holdings, Inc.的季度营收约是Embecta Corp.的1.9倍（$501.3M vs $261.2M），FirstCash Holdings, Inc.净利率更高（20.8% vs 16.9%，领先3.9%），FirstCash Holdings, Inc.同比增速更快（21.2% vs -0.3%），过去两年FirstCash Holdings, Inc.的营收复合增速更高（16.9% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
FirstCash Holdings, Inc.是总部位于美国得克萨斯州沃斯堡的典当企业，在美国及拉丁美洲多地运营线下典当零售门店，为纳斯达克证券交易所公开上市企业，在美洲典当服务领域拥有成熟的业务布局与完善的运营网络。
EMBC vs FCFS — 直观对比
营收规模更大
FCFS
是对方的1.9倍
$261.2M
营收增速更快
FCFS
高出21.4%
-0.3%
净利率更高
FCFS
高出3.9%
16.9%
两年增速更快
FCFS
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $501.3M |
| 净利润 | $44.1M | $104.2M |
| 毛利率 | 61.9% | — |
| 营业利润率 | 31.9% | 28.5% |
| 净利率 | 16.9% | 20.8% |
| 营收同比 | -0.3% | 21.2% |
| 净利润同比 | — | 24.7% |
| 每股收益（稀释后） | $0.74 | $2.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCFCFS
| Q4 25 | $261.2M | $501.3M | ||
| Q3 25 | $264.0M | $411.0M | ||
| Q2 25 | $295.5M | $385.1M | ||
| Q1 25 | $259.0M | $371.1M | ||
| Q4 24 | $261.9M | $413.7M | ||
| Q3 24 | $286.1M | $363.1M | ||
| Q2 24 | $272.5M | $363.5M | ||
| Q1 24 | $287.2M | $366.8M |
净利润EMBCFCFS
| Q4 25 | $44.1M | $104.2M | ||
| Q3 25 | $26.4M | $82.8M | ||
| Q2 25 | $45.5M | $59.8M | ||
| Q1 25 | $23.5M | $83.6M | ||
| Q4 24 | $0 | $83.5M | ||
| Q3 24 | $14.6M | $64.8M | ||
| Q2 24 | $14.7M | $49.1M | ||
| Q1 24 | $28.9M | $61.4M |
毛利率EMBCFCFS
| Q4 25 | 61.9% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | 66.7% | — | ||
| Q1 25 | 63.4% | — | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 60.7% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 64.6% | — |
营业利润率EMBCFCFS
| Q4 25 | 31.9% | 28.5% | ||
| Q3 25 | 21.4% | 27.4% | ||
| Q2 25 | 31.8% | 21.1% | ||
| Q1 25 | 24.3% | 30.0% | ||
| Q4 24 | 11.0% | 26.5% | ||
| Q3 24 | 9.2% | 23.5% | ||
| Q2 24 | 20.5% | 18.2% | ||
| Q1 24 | 13.6% | 22.3% |
净利率EMBCFCFS
| Q4 25 | 16.9% | 20.8% | ||
| Q3 25 | 10.0% | 20.1% | ||
| Q2 25 | 15.4% | 15.5% | ||
| Q1 25 | 9.1% | 22.5% | ||
| Q4 24 | — | 20.2% | ||
| Q3 24 | 5.1% | 17.9% | ||
| Q2 24 | 5.4% | 13.5% | ||
| Q1 24 | 10.1% | 16.7% |
每股收益（稀释后）EMBCFCFS
| Q4 25 | $0.74 | $2.35 | ||
| Q3 25 | $0.44 | $1.86 | ||
| Q2 25 | $0.78 | $1.34 | ||
| Q1 25 | $0.40 | $1.87 | ||
| Q4 24 | $0.00 | $1.86 | ||
| Q3 24 | $0.24 | $1.44 | ||
| Q2 24 | $0.25 | $1.08 | ||
| Q1 24 | $0.50 | $1.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $125.2M |
| 总债务越低越好 | — | $2.2B |
| 股东权益账面价值 | $-613.1M | $2.3B |
| 总资产 | $1.1B | $5.3B |
| 负债/权益比越低杠杆越低 | — | 0.98× |
8季度趋势，按日历期对齐
现金及短期投资EMBCFCFS
| Q4 25 | $201.3M | $125.2M | ||
| Q3 25 | $225.5M | $130.2M | ||
| Q2 25 | $230.6M | $101.5M | ||
| Q1 25 | $209.3M | $146.0M | ||
| Q4 24 | $210.0M | $175.1M | ||
| Q3 24 | $267.5M | $106.3M | ||
| Q2 24 | $275.1M | $113.7M | ||
| Q1 24 | $299.8M | $135.1M |
总债务EMBCFCFS
| Q4 25 | — | $2.2B | ||
| Q3 25 | $1.4B | $2.2B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $1.6B | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.5B |
股东权益EMBCFCFS
| Q4 25 | $-613.1M | $2.3B | ||
| Q3 25 | $-650.6M | $2.2B | ||
| Q2 25 | $-669.6M | $2.1B | ||
| Q1 25 | $-736.2M | $2.1B | ||
| Q4 24 | $-768.8M | $2.1B | ||
| Q3 24 | $-738.3M | $2.0B | ||
| Q2 24 | $-763.7M | $2.0B | ||
| Q1 24 | $-769.6M | $2.0B |
总资产EMBCFCFS
| Q4 25 | $1.1B | $5.3B | ||
| Q3 25 | $1.1B | $5.2B | ||
| Q2 25 | $1.2B | $4.5B | ||
| Q1 25 | $1.1B | $4.4B | ||
| Q4 24 | $1.1B | $4.5B | ||
| Q3 24 | $1.3B | $4.4B | ||
| Q2 24 | $1.3B | $4.3B | ||
| Q1 24 | $1.2B | $4.2B |
负债/权益比EMBCFCFS
| Q4 25 | — | 0.98× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 0.79× | ||
| Q1 25 | — | 0.83× | ||
| Q4 24 | — | 0.85× | ||
| Q3 24 | — | 0.87× | ||
| Q2 24 | — | 0.85× | ||
| Q1 24 | — | 0.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $206.6M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | — |
| 自由现金流率自由现金流/营收 | 6.4% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 0.39× | 1.98× |
| 过去12个月自由现金流最近4个季度 | $205.8M | — |
8季度趋势，按日历期对齐
经营现金流EMBCFCFS
| Q4 25 | $17.2M | $206.6M | ||
| Q3 25 | $84.0M | $135.8M | ||
| Q2 25 | $81.2M | $116.9M | ||
| Q1 25 | $31.8M | $126.6M | ||
| Q4 24 | $-5.3M | $198.1M | ||
| Q3 24 | $26.6M | $113.1M | ||
| Q2 24 | $-2.1M | $106.2M | ||
| Q1 24 | $24.3M | $122.5M |
自由现金流EMBCFCFS
| Q4 25 | $16.6M | — | ||
| Q3 25 | $76.7M | — | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $31.7M | — | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-11.8M | — | ||
| Q1 24 | $20.9M | — |
自由现金流率EMBCFCFS
| Q4 25 | 6.4% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 27.3% | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.3% | — | ||
| Q1 24 | 7.3% | — |
资本支出强度EMBCFCFS
| Q4 25 | 0.2% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 1.2% | — |
现金转化率EMBCFCFS
| Q4 25 | 0.39× | 1.98× | ||
| Q3 25 | 3.18× | 1.64× | ||
| Q2 25 | 1.78× | 1.95× | ||
| Q1 25 | 1.35× | 1.51× | ||
| Q4 24 | — | 2.37× | ||
| Q3 24 | 1.82× | 1.74× | ||
| Q2 24 | -0.14× | 2.16× | ||
| Q1 24 | 0.84× | 2.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
FCFS
| US Pawn Segment | $292.2M | 58% |
| Retail POS Payment Solutions | $209.8M | 42% |
